Health & Finance

Medicare's 2026 'Savings' Are Actually a Windfall for Insurers

Don't let the headlines fool you: new rules mean more cash for Advantage plans, not necessarily lower costs for you.

By Neil D'Monte, Palmelle Editorial Team · Reviewed by Neil D'Monte · 7 min read · 2026-07-08

SHORT ANSWER

New Medicare rules for 2026 are projected to inject over $13 billion into Medicare Advantage plans, significantly benefiting insurers, while the actual cost savings for beneficiaries remain uncertain.

The direct answer

The conventional wisdom suggests upcoming Medicare changes for 2026 will bring relief through lower drug prices and managed out-of-pocket expenses. However, a closer look reveals a significant shift in favor of Medicare Advantage (MA) insurers. The Centers for Medicare & Medicaid Services (CMS) finalized policies projecting a net average increase of 2.48% in MA payments for 2027, amounting to over $13 billion in additional funds for these private plans

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link

. This substantial 'cash injection,' as one analyst put it, is a direct tailwind for major MA players like UnitedHealth Group, Humana, and CVS Health, who stand to benefit from higher reimbursement rates

Medicare Advantage just got a massive cash injection 💰 Trump admin finalizes Star Ratings overhaul — $18B in extra payments flowing to health insurers. This is a direct tailwind for the big MA players: $UNH , $HUM , $CVS , $ELV , $CNC all stand to benefit from higher reimbursement…
— Casey | Trade Tracs link

. While some changes aim to control costs for beneficiaries, the substantial financial boost to insurers suggests the true winners of these policy adjustments may not be the seniors they are intended to serve.

The 'Star Ratings' Overhaul and Its Hidden Benefits

The conventional take on Medicare Advantage is that it offers more comprehensive benefits. However, recent policy shifts, particularly the finalized Star Ratings overhaul, are injecting billions into insurer coffers. The Trump administration's approach, continued by subsequent policies, finalized a Star Ratings overhaul that provides an estimated $18 billion in extra payments to health insurers

Medicare Advantage just got a massive cash injection 💰 Trump admin finalizes Star Ratings overhaul — $18B in extra payments flowing to health insurers. This is a direct tailwind for the big MA players: $UNH , $HUM , $CVS , $ELV , $CNC all stand to benefit from higher reimbursement…
— Casey | Trade Tracs link

. This isn't a minor tweak; it's a significant financial boost directly benefiting large MA providers like UnitedHealth, Humana, and CVS

Medicare Advantage just got a massive cash injection 💰 Trump admin finalizes Star Ratings overhaul — $18B in extra payments flowing to health insurers. This is a direct tailwind for the big MA players: $UNH , $HUM , $CVS , $ELV , $CNC all stand to benefit from higher reimbursement…
— Casey | Trade Tracs link

. The CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average increase of 2.48%, which translates to more than $13 billion in additional MA payments

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link

. This move, which keeps the 2024 MA risk adjustment model and excludes certain diagnoses from risk calculations, essentially means insurers receive higher payments with fewer adjustments, a clear win for their bottom line.

Why Your Out-of-Pocket Costs Might Not Budge

While Medicare is touting changes that could lower prescription drug costs and adjust out-of-pocket limits for Part D beneficiaries, the underlying financial flows suggest these benefits might be offset. The significant increase in payments to Medicare Advantage plans, projected at 2.48% for 2027

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link

, means insurers have more revenue. However, this doesn't automatically translate to lower costs for enrollees. The system is complex, and increased insurer revenue often gets absorbed into higher administrative costs or expanded, but not necessarily cheaper, benefit packages. The focus on prior authorization pilots for Part B services also signals a move towards stricter 'utilization management' – a polite industry term for controlling access, which can lead to delays and frustration for seniors needing care.

The Market's Reaction: A Clear Indicator

The financial markets reacted swiftly and positively to the CMS's finalized Medicare Advantage payment policies. Stocks of major health insurers surged in after-hours trading, with UnitedHealth Group (UNH) seeing a significant boost [c3, c4]. This reaction underscores the industry's perspective: the finalized rates were 'much better-than-expected'

Everything you need to know about the CMS news, and what it means for $UNH and $OSCR : $UNH surged after CMS finalized a much better-than-expected Medicare Advantage rate update for 2027. The headline rate came in at +2.48%, far above the +1.0% many were bracing for, and CMS…
— Stocker-Man link

. When analysts were bracing for a lower increase, the actual 2.48% projection was a cause for celebration among investors

Everything you need to know about the CMS news, and what it means for $UNH and $OSCR : $UNH surged after CMS finalized a much better-than-expected Medicare Advantage rate update for 2027. The headline rate came in at +2.48%, far above the +1.0% many were bracing for, and CMS…
— Stocker-Man link

. This isn't just about numbers on a balance sheet; it’s a clear signal that the policy changes are viewed as a substantial financial positive for the companies administering Medicare benefits, reinforcing the idea that the 'savings' are flowing upstream to the insurers, not downstream to the beneficiaries.

A SCENE

Eleanor, 78, lives on a fixed income in her modest apartment. She relies on Medicare Part D for her heart medication, which has been a consistent, albeit significant, expense. This year, she heard news about Medicare negotiating drug prices and capping out-of-pocket costs for 2026, and felt a flicker of hope. Her neighbor, Frank, who recently switched to a Medicare Advantage plan, mentioned his plan covers a new physical therapy program he's been wanting to try. Eleanor considers switching too, lured by the promise of extra benefits. However, she's also heard whispers from her son, who works in healthcare finance, about how Medicare Advantage plans are getting a substantial funding boost from the government. He explained that while the headlines sound good, the increased payments to insurers might not trickle down as lower premiums or drug costs for her. He advised her to look closely at her current Part D plan's projected costs for next year and compare them to the *actual* out-of-pocket expenses she’d face under a new Advantage plan, not just the advertised benefits. He specifically told her to ask any potential Advantage plan representative about the precise drug formulary for her medications and the exact co-pays for Part B services, especially those that might be subject to prior authorization, before making any decisions. The promise of lower costs feels distant, overshadowed by the complex reality of insurance economics.

Common mistakes

Focusing solely on the positive aspects of drug price negotiation.
This ignores the broader financial implications for insurers and the potential for cost-shifting elsewhere in the system. The significant increase in Medicare Advantage payments is a crucial counterpoint.
Presenting Medicare Advantage as a universally beneficial option.
While Advantage plans offer additional benefits, the underlying financial incentives for insurers and the potential for restrictive 'utilization management' are often overlooked by beneficiaries.
Using vague language about 'cost savings' without specific figures.
The article needs to quantify the impact, such as the billions injected into MA plans, to provide concrete understanding rather than general awareness.

PALMELLE'S VIEW

In our view, the narrative around Medicare's 2026 updates is intentionally misleading. While the public sees headlines about lower drug prices and better out-of-pocket limits, the core of these changes is a massive financial boon for private Medicare Advantage insurers. The finalized payment policies for 2027 show a projected net average increase of 2.48%, translating to over $13 billion in extra payments for these companies

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link

. This isn't about saving seniors money; it's about subsidizing the industry. As analyst Casey noted, this is a 'massive cash injection' for big MA players

Medicare Advantage just got a massive cash injection 💰 Trump admin finalizes Star Ratings overhaul — $18B in extra payments flowing to health insurers. This is a direct tailwind for the big MA players: $UNH , $HUM , $CVS , $ELV , $CNC all stand to benefit from higher reimbursement…
— Casey | Trade Tracs link

, a sentiment echoed by others who saw stocks surge on the news [c3, c4]. We need to question who these policies truly serve.

BOTTOM LINE

Before open enrollment, call your current Medicare Part D provider and ask for a precise estimate of your prescription costs for 2026, then compare that figure to the out-of-pocket maximums and co-pays for your specific medications under any Medicare Advantage plan you are considering.

WHEN THIS CHANGES

The actual impact on your healthcare costs and access to services will depend on the specific Medicare Advantage plan you choose or your current Original Medicare coverage, as well as the drugs you take. The financial projections for insurer payments are for 2027, but changes affecting beneficiaries are effective starting in 2026. Continuously review your plan options during open enrollment periods.

Frequently asked

Will my prescription drug costs definitely go down in 2026?

Some drug costs may decrease due to Medicare's negotiation power. However, the impact varies by drug and plan. The significant increase in funding for Medicare Advantage plans could also influence overall costs, and it's crucial to check your specific plan's formulary and co-pays.

What is the 'Star Ratings' overhaul?

It's a system CMS uses to rate Medicare Advantage and Part D plans. Changes to this system have resulted in substantial additional payments to insurers, estimated at $18 billion, based on plan performance and quality metrics.

Are Part B services being affected by these changes?

Yes, there's a pilot program for prior authorization for certain Part B services. This means insurers may require pre-approval for some treatments or procedures, potentially adding administrative hurdles and delays for beneficiaries.

Medicare's 2026 'Savings' Are Actually a Windfall for Insurers

The direct answer

The 'Star Ratings' Overhaul and Its Hidden Benefits

Why Your Out-of-Pocket Costs Might Not Budge

The Market's Reaction: A Clear Indicator

Common mistakes

Frequently asked

Sources

Keep reading